

Synthesis and theoretical activity evaluation of a new steroid-oxazolone derivative against COX1-1 and COX-2

Rosas-Nexticapa Marcela¹, Figueroa-Valverde Lauro^{2,*}, Díaz-Cedillo Francisco³, Mateu-Armand Virginia¹, Garcimarrero-Espino E. Alejandra¹, Hernandez-Vasquez Patricia¹, Benitez-Coeto Laura¹, Lopez-Gutierrez Tomas², López-Ramos Maria², Hau-Heredia Lenin², Pool-Gómez Eduardo², Cabrera-TuzJhair², Borges-BalloteYaritza², Ortiz-AkeYazmin²

¹Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Av. Agustín Melgar s/n, Col Buenavista C.P. 24039 Campeche, Camp., México.

²Facultad de Nutrición, Universidad Veracruzana, Médicos y Odontólogos s/n C.P. 91010, Unidad del Bosque Xalapa Veracruz, México.

³Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional. Prol. Carpio y Plan de Ayala s/n Col. Santo Tomas, México.

*corresponding author e-mail address: lfiguero@uacam.mx; lauro_1999@yahoo.com;

ABSTRACT

There are some reports for the preparation of several drugs as cyclooxygenase (COX) inhibitors; however, some reagents used in the preparation are expensive and difficult to handle. The aim of this study was to synthesize a steroid-oxazolone derivative using some reactions such as *i*) hydroxylation-amination; *ii*) amidation; *iii*) alkynyl-addition; *iv*) aldolization and *iv*) imination. In addition, a theoretical assay was carried out to evaluate the interaction of both COX-1 and COX-2 with the steroid-oxazolone derivative using indomethacin and rofecoxib as controls in a docking model. The structure of the compounds obtained was confirmed through elemental analysis, spectroscopy and spectrometry data. The results showed that there are differences between the interaction of the steroid-oxazolone derivative with both COX 1 and COX 2 compared with the bound of indomethacin and rofecoxib with this type of enzymes. These data suggest that the steroid-oxazolone derivative could be a good candidate as COX-inhibitor translated as a possible drug for treatment of pain.

Keywords: *Synthesis, cyclooxygenase, inhibitor, steroid, oxazolone, derivative.*

1. INTRODUCTION

For years, several inhibitors of the enzyme cyclooxygenase have been used for the treatment of both inflammation and pain such as ketorolac, naproxen, acetylsalicylic acid, paracetamol, ibuprofen, indomethacin [1, 2] and others. However, some of these drugs can produce side effects such as bronchospasm, vasomotor rhinitis, and angioedema [3], renal dysfunction, meningeal syndrome, bone marrow depression, headache and vertigo [4-6]. In the search of other alternative therapeutics for the treatment of these clinical pathologies, several drugs have been prepared such as 1-morpholino-cyclohexanecarbonitrile from both morpholine and cyclohexanone [7]. Other data showed the reaction of Ethyl 5-(4-nitrophenyl)furan-2-carboxylate with hydrazine to form 5-(4-nitrophenyl) furan-2-carbohydrazide [8]. In addition, a series of 3-

(4-biphenyl)-5-substituted phenyl-2-pyrazolines were synthesized from both chalcones and hydrazine with biological activity to pain [9]. Also, a study showed the synthesis of 4-aminopiperidine derivative with analgesic activity through the reaction of (1-Benzylpiperidin-4-yl)-[2-(3,4-dimethoxyphenyl)ethyl]-amine with 5-bromo-2-(3,4-dimethoxyphenyl)-2-(methylethyl) pentanenitrile [10]. All these data indicate that some methods are available for synthesis of drugs with analgesic activity; nevertheless, expensive reagents and special conditions are required. Therefore, in this study, a steroid-oxazolone derivative was synthesized and theoretical activity evaluation against both COX1-1 (2OYU) and COX-2 (3LN1) [11].

2. MATERIALS AND METHODS

2.1 General methods.

2-nitroestrone was prepared using a previously method reported [12]; in addition, the other reagents used in this investigation were acquired from Sigma-Aldrich Co., Ltd. The melting point for compounds was determined on an Electrothermal (900 model). Infrared spectra (IR) were recorded using KBr pellets on a Perkin Elmer Lambda 40 spectrometer. ¹H and ¹³C NMR spectra were recorded on a Varian VXR300/5 FT NMR spectrometer at 300 MHz in CDCl₃ using TMS as internal standard. EIMS spectra were obtained with a Finnigan Trace Gas Chromatography Polaris

Q-Spectrometer. Elementary analysis data were acquired from a Perkin Elmer Ser. II CHNS/02400 elemental analyzer.

2.2 Chemical Synthesis.

(13S)-3-((1-hydroxyethyl)amino)-13-methyl-2-nitro-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (2)

In a round bottom flask (10 ml), 2-nitroestrone (200 mg, 0.63 mmol) and acetonitrile (5ml) were stirred to reflux for 12 h. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water (4:1) system; yielding 44% of product; m.p. 166-168 °C; IR (V_{max}, cm⁻¹) 3430, 3400,

1712 and 1544: ^1H NMR (500 MHz, Chloroform-*d*) δ_{H} : 0.90 (s, 3H), 1.20-1.34 (m, 4H), 1.44 (s, 3H), 1.54-2.46 (m, 8H), 3.02-3.10 (m, 3H), 5.60 (m, 1H), 6.56 (m, 1H), 7.72 (broad, 2H), 8.42 (m, 1H) ppm. ^{13}C NMR (500 MHz, Chloroform-*d*) δ_{C} : 13.82, 21.70, 24.90, 25.50, 27.55, 28.94, 31.06, 35.00, 37.25, 46.43, 48.34, 50.12, 76.62, 115.44, 124.70, 128.92, 137.2, 141.00, 147.80, 219.74 ppm. EI-MS *m/z*: 358.18. Anal. Calcd. for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_4$: C, 67.02; H, 7.31; N, 7.82; O, 17.85. Found: C, 67.00; H, 7.24.

(12aS)-8,12a-dimethyl-2,3,3a,3b,4,5,7,8,10b,11,12,12a-dodecahydro-1H-cyclopenta [7,8]phenanthro[2,3-d]oxazol-1-one (3)

In a round bottom flask (10 ml), compound **2** (200 mg, 0.58 mmol), potassium carbonate (45 mg, 0.33 mmol), and 5 ml of dimethyl sulfoxide were stirred to reflux for 12 h. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water:hexane (4:1:1) system; yielding 67% of product; m.p. 122-124 °C; IR (V_{max} , cm^{-1}) 3432, 1710 and 1210: ^1H NMR (300 MHz, Chloroform-*d*) δ_{H} : 0.90 (s, 3H), 1.18 (s, 3H), 1.22-1.90 (m, 7H), 2.10-3.10 (m, 8H), 6.24 (m, 1H), 6.43-6.54 (m, 2H), 7.22 (broad, 1H) ppm. ^{13}C NMR (300 MHz, Chloroform-*d*) δ_{C} : 13.80, 19.91, 21.82, 25.84, 27.55, 28.92, 31.50, 35.40, 37.56, 46.90, 48.12, 50.40, 83.50, 107.22, 110.92, 131.32, 133.26, 136.02, 144.00, 220.70 ppm. EI-MS *m/z*: 311.18. Anal. Calcd. for $\text{C}_{20}\text{H}_{25}\text{NO}_2$: C, 77.14; H, 8.09; N, 4.50; O, 10.28. Found: C, 77.10; H, 10.19.

(12aS)-7-(2-chloroacetyl)-8,12a-dimethyl-2,3,3a,3b,4,5,7,8, 10b, 11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d] oxazol-1-one (4)

In a round bottom flask (10 ml), compound **3** (200 mg, 0.64 mmol), chloroacetyl chloride (50 μl , 0.63 mmol) and triethylamine (100 μl , 0.71 mmol) in 5 mL of methanol was stirring for 72 h to room temperature. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water (4:2) system; yielding 54% of product; m.p. 136-138 °C; IR (V_{max} , cm^{-1}) 1712, 1632 and 1210: ^1H NMR (300 MHz, Chloroform-*d*) δ_{H} : 0.90 (s, 3H), 1.22-1.36 (m, 4H), 1.40 (s, 3H), 1.55-2.20 (m, 7H), 2.46-2.62 (m, 4H), 3.92-4.00 (m, 2H), 6.40 (m, 1H), 6.73-7.30 (m, 2H) ppm. ^{13}C NMR (300 MHz, Chloroform-*d*) δ_{C} : 13.80, 19.90, 21.74, 25.70, 27.63, 28.92, 31.32, 35.30, 37.45, 42.42, 46.87, 48.10, 50.22, 82.84, 109.40, 116.23, 133.00, 134.00, 135.40, 152.97, 160.82, 220.30 ppm. EI-MS *m/z*: 387.16. Anal. Calcd. for $\text{C}_{22}\text{H}_{26}\text{ClNO}_3$: C, 68.12; H, 6.76; Cl, 9.14, N, 3.61; O, 12.37. Found: C, 68.06; H, 6.70.

(12aS)-7-(7-hydroxyhept-2-ynoyl)-8,12a-dimethyl-2,3,3a,3b, 4,5,7,8,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d]oxazol-1-one (5)

In a round bottom flask (10 ml), compound **4** (310 mg, 0.80 mmol), 5-hexyn-1-ol (90 μl , 0.82 mmol) and Copper(II) chloride (110 μl , 0.82 mmol) in 5 mL of methanol was stirring for 72 h to room temperature. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water (4:1) system; yielding 65% of product; m.p. 106-108 °C; IR (V_{max} , cm^{-1}) 3400, 2196, 1712, 16390 and 1212: ^1H NMR (300 MHz, Chloroform-*d*) δ_{H} : 0.90 (s, 3H), 1.22-1.36 (m, 4H), 1.40 (s, 3H), 1.55 (m, 1H), 1.58-1.72 (m, 4H), 1.80-1.90 (m, 2H), 1.94 (broad, 1H), 2.10-2.20 (m, 4H), 2.25-2.26 (m, 2H), 2.46-2.62 (m, 4H),

3.62-(m, 2H), 6.40 (m, 1H), 6.60-7.40 (m, 2H) ppm. ^{13}C NMR (300 MHz, Chloroform-*d*) δ_{C} : 13.80, 17.62, 19.00, 21.74, 25.71, 25.75, 27.60, 28.92, 30.04, 31.35, 35.32, 37.42, 46.87, 48.10, 50.24, 62.05, 73.96, 82.95, 90.12, 109.52, 116.02, 133.10, 133.92, 135.40, 149.62, 152.82, 220.30 ppm. EI-MS *m/z*: 435.24. Anal. Calcd. for $\text{C}_{27}\text{H}_{33}\text{NO}_4$: C, 74.45; H, 7.64; N, 3.22; O, 14.69. Found: C, 74.40; H, 7.60

8-((12aS)-8,12a-dimethyl-1-oxo-2,3,3a,3b,4,5,10b,11,12,12a-decahydro-1H-cyclopenta [7,8]phenanthro[2,3-d]oxazol-7(8H)-yl)-8-oxooct-6-ynal (6)

In a round bottom flask (10 ml), compound **5** (200 mg, 0.46 mmol) 5 mL of dimethyl sulfoxide was stirring for 72 h to reflux. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water:hexane (4:1:1) system; yielding 48% of product; m.p. 116-118 °C; IR (V_{max} , cm^{-1}) 2194, 1726, 1710 and 1210: ^1H NMR (300 MHz, Chloroform-*d*) δ_{H} : 0.90 (s, 3H), 1.22-1.36 (m, 4H), 1.40 (s, 3H), 1.55 (m, 1H), 1.70-1.76 (m, 4H), 1.80-2.10 (m, 4H), 2.12 (m, 1H), 2.13-2.14 (m, 2H), 2.20-2.54 (m, 3H), 2.56 (m, 2H), 2.62-2.63 (m, 2H), 6.40 (m, 1H), 6.60-7.40 (m, 2H), 9.70 (d, 1H, $J = 1.00$ Hz) ppm. ^{13}C NMR (300 MHz, Chloroform-*d*) δ_{C} : 13.80, 18.15, 19.00, 21.70, 22.10, 25.71, 25.76, 27.62, 28.93, 31.34, 35.32, 37.42, 44.57, 46.86, 48.10, 50.22, 73.97, 82.97, 91.32, 109.52, 116.02, 133.10, 133.92, 135.40, 149.61, 152.82, 202.44, 220.30 ppm. EI-MS *m/z*: 447.24. Anal. Calcd. for $\text{C}_{27}\text{H}_{33}\text{NO}_4$: C, 75.14; H, 7.43; N, 3.13; O, 14.30. Found: C, 75.10; H, 7.38.

(12aS)-7-((1Z,4E)-1,4-diazacyclododeca-4,12-dien-6-yn-5-yl)-8, 12a-dimethyl-2,3,3a,3b,4,5,7,8,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[2,3-d]oxazol-1-one (7)

In a round bottom flask (10 ml), compound **6** (200 mg, 0.45 mmol), ethylenediamine (50 μl , 0.74 mmol) and boric acid (50 mg, 0.80 mmol) in 5 mL of methanol was stirring for 72 h to room temperature. The solution obtained was reduced pressure and purified through a crystallization using the methanol:water (4:1) system; yielding 65% of product; m.p. 146-148 °C; IR (V_{max} , cm^{-1}) 3322, 2196, 1712 and 1212: ^1H NMR (300 MHz, Chloroform-*d*) δ_{H} : 0.85 (m, 1H), 0.90 (s, 3H), 1.22-1.36 (m, 4H), 1.46 (m, 2H), 1.55 (m, 1H), 1.57 (s, 3H), 1.58 (m, 2H), 1.80-2.20 -2.54 (m, 6H), 2.30 (m, 2H), 2.46-3.10 (m, 4H), 4.30-4.50 (m, 1H), 6.60 (m, 1H), 6.70 (m, 1H), 6.80 (m, 1H), 6.88 (m, 1) ppm. ^{13}C NMR (300 MHz, Chloroform-*d*) δ_{C} : 13.80, 19.42, 19.91, 21.70, 23.03, 25.70, 27.64, 28.60, 28.92, 31.34, 34.44, 35.32, 34.44, 46.85, 48.10, 48.42, 50.00, 50.24, 88.44, 91.53, 97.96, 108.65, 115.12, 131.70, 132.66, 133.45, 145.46, 149.72, 159.86, 220.30 ppm. EI-MS *m/z*: 471.28. Anal. Calcd. for $\text{C}_{30}\text{H}_{37}\text{N}_3\text{O}_2$: C, 76.40; H, 7.91; N, 8.91; O, 6.78. Found: C, 76.34; H, 7.88.

2.3 Physicochemical parameters evaluation.

Some electronic parameters such as HOMO (Highest Occupied Molecular Orbital), LUMO (Lowest Unoccupied Molecular Orbital) energy, orbital coefficients distribution, molecular dipole moment and HBD (hydrogen bond donor groups) and HBA (hydrogen bond acceptor groups) and PSA (polar surface area) were evaluated using the SPARTAN'06 software [13].

2.4 Pharmacophore evaluation.

The 3D pharmacophore model for the compounds 6 and 7 was determinate using LigandScout 4.08 software [14]

3. RESULTS

3.1 Chemical synthesis.

Several oxazolone analogs have prepared using some reagents such as $[(\text{Ph}_3\text{P})\text{Au}(\text{NCMe})]\text{Sb}_6$ complex [16], $\text{N,N}'$ -terephthaloylbis-(*dl*-alanine) [17], resin [18], $\text{Ph}_3\text{P-CBr}_4$ adducts [19], palladium [20] and others. In this study, a steroid-oxazolone derivative was prepared using some strategies; the first stage was achieved via reaction of 2-nitroestrone with acetonitrile to form an amino-ethanol complex (Figure 1 and 2).




Figure 1. Preparation of a chloroacetyl-steroid-oxazolone derivative (4). Reaction of 2-nitroestrone with acetonitrile (i) to form a hydroxyethylamino-nitro-estrone (2). Then, an steroid oxazolone (3) via displacement of nitro group by hydroxyl in $\text{DMSO}/\text{K}_2\text{CO}_3$ (ii) presence of reacted with. Finally, 3 reacted with chloroacetyl chloride (iii) to form 4.

The ^1H NMR showed several signals for 2 at 0.90 ppm for methyl group bound to steroid nucleus; at 1.44 ppm for methyl bound to both hydroxyl and methylamine; at 1.20-1.34, 1.54-3.10, 6.56 and 8.42 ppm for steroid moiety; at 5.60 ppm for methylene group bound to both amino and hydroxyl groups; at 7.72 for both hydroxyl and amine groups. The ^{13}C NMR display some signals at 13.82 ppm for methyl group; at 24.90 for methyl bound to both hydroxyl and methylamine; at 21.70, 25.50-50.12 and 115.44-147.80 ppm for steroid moiety; at 76.62 ppm for methylene group bound to both amino and hydroxyl groups; at 219.70 ppm for ketone group. In addition, the mass spectrum from 2 showed a molecular ion (m/z) 358.18.




Figure 2. Mechanism of reaction involved in the synthesis of hydroxyethylamino-nitro-estrone.

The second stage was achieved by the synthesis of an ether-steroid derivative (3); it is important to mention that some reports have been reported for the preparation of ether derivatives via displacement of nitro group using methoxide as dipolar aprotic solvent [21, 22]. In this study, 3 was prepared using a previously method reported [23]; the reaction was carried out through

2.5 Theoretical evaluation of the interaction between compound 4 and kinase-2 protein (3FL5).

The interaction of compound 4 with both COX1-1 (2OYU) and COX-2 (3LN1) [11] was carried out using a DockingServer [15].

intramolecular displacement from nitro group by the hydroxyl group of the compound 2 in presence of $\text{DMSO}/\text{K}_2\text{CO}_3$ (Figure 1). The ^1H NMR showed several signals for 3 at 0.90 ppm for methyl group bound to steroid nucleus; at 1.18 ppm for methyl bound to oxazole ring; at 1.22-3.10 and 6.43-6.54 ppm for steroid moiety; at 6.24 ppm for oxazole ring; at 7.72 for both hydroxyl and amine groups. The ^{13}C NMR display some signals at 13.80 ppm for methyl group; at 19.91 for methyl bound to oxazole ring; at 21.82-50.40 and 107.22-144.00 ppm for steroid moiety; at 83.50 for oxazole ring; at 220.70 ppm for ketone group. Finally, the mass spectrum from 3 showed a molecular ion (m/z) 311.18.




Figure 3. Synthesis of 1,4-diazacyclododeca-4,12-dien-6-yn-5-yl-steroid-oxazolone (7). Reaction of chloroacetyl-steroid-oxazolone derivative (4) with 5-hexyn-1-ol to form hydroxyhept-2-ynoyl-steroid-oxazolone (5) in presence of Copper(II) chloride (iv). Then, an oxazol-steroid-8-oxooctynal (6) was prepared via reaction of 5 with dimethyl sulfide (v). Finally, 6 reacted with ethylenediamine to form 7.

On the other hand, a chloroamide-steroid derivative (4) was prepared (Figure 1); it is important to mention that there are many procedures for the formation of chloroamides which are known in the literature, for example the reaction of amine with trichloroisocyanuric acid [24] or amide secondary with *N*-chlorobenzotriazole to form a chloroamide derivative [25]; in addition, have been prepared some chloroamide groups using chloroacetyl chloride [26]. The ^1H NMR showed several signals for 4 at 0.90 ppm for methyl group bound to steroid nucleus; at 1.40 ppm for methyl bound to oxazole ring; at 1.22-2.62 and 6.73-7.30 ppm for steroid moiety; at 3.92-4.00 ppm for methylene group of chloroamide; at 6.40 ppm for oxazole ring. The ^{13}C NMR display some signals at 13.80 ppm for methyl group; at 19.90 for methyl bound to oxazole ring; at 21.74-37.45, 46.87-50.22, 109.40-152.97 ppm for steroid moiety; at 42.42 ppm methylene group of chloroamide; at 88.84 for oxazole ring; at 160.82 ppm for amide group; at 220.30 ppm for ketone group. Additionally, the mass spectrum from 4 showed a molecular ion (m/z) 387.16. The following stage involves the synthesis of a propargylic-amide derivative (5). It is noteworthy that several propargylic-amide

analogues have been prepared [27, 28]; however, some reagents are dangerous and are difficult to handle. Therefore in this study, **5** was prepared via addition 5-hexyn-1-ol to **4** in presence of Copper(II) chloride (Figure 3). The ¹HNMR showed several signals for **5** at 0.90 ppm for methyl group bound to steroid nucleus; at 1.40 ppm for methyl bound to oxazole ring; at 1.22-1.36, 1.55, 1.80-1.90, 2.10-2.20, 2.46-2.62 and 6.60-7.40 ppm for steroid moiety; at 1.58-1.72, 2.26 and 3.62 ppm for arm bound to both alkyne and hydroxyl groups; at 1.94 ppm for hydroxyl group; at 6.40 ppm for oxazole ring. The ¹³CNMR display some signals at 13.80 ppm for methyl bound to steroid nucleus; at 19.90 ppm for methyl bound to oxazole ring; at 17.62, 25.78, 30.04, 62.05, 109.50-135.40 and 152.82 ppm for arm bound to both alkyne and hydroxyl groups; at 21.74-25.71, 27.60-28.92 and 31.35-50.24 ppm for steroid moiety; at 73.96 and 90.12 ppm for both alkyne group; at 82.95 for oxazole ring; at 119.62 ppm for amide group; at 220.30 ppm for ketone group. Additionally, the mass spectrum from **5** showed a molecular ion (m/z) 435.24.

In addition, **5** was reacted with dimethyl sulfoxide to form an aldehyde-oxazolone-steroid derivative using a previous method reported for synthesis of aldehyde groups [29]. The ¹HNMR showed several signals for **6** at 0.90 ppm for methyl group bound to steroid nucleus; at 1.40 ppm for methyl bound to oxazole ring; at 1.22-1.36, 1.54, 1.80-2.10, 2.13, 2.20-2.54, 2.62-2.63 and 6.60-7.40 ppm for steroid moiety; at 1.70-1.76, 2.12-2.14 and 2.56 ppm for arm bound to both alkyne and hydroxyl groups; at 1.94 ppm for hydroxyl group; at 6.40 ppm for oxazole ring; at 9.70 ppm for aldehyde group. The ¹³CNMR display some signals at 13.80 ppm for methyl bound to steroid nucleus; at 19.90 ppm for methyl group bound to oxazole ring; at 18.15, 22.10, 25.76, 44.57 for arm bound to both aldehyde and alkyne group; at 21.70, 25.71, 27.62-37.42, 46.86-50.22, 109.52-135.40 and 152.82 ppm for steroid moiety; at 73.97 and 91.32 ppm for alkyne group; at 82.97 ppm for oxazole ring; at 208.44 ppm for aldehyde group; at 220.30 ppm for ketone group. In addition, the mass spectrum from **6** showed a molecular ion (m/z) 447.24.

Finally, a 1,4-diaza-cyclododeca-4,12-dien-6-yne derivative was prepared via reaction of **6** with ethylenediamine to form imino groups of the 1,4-diazacyclododeca-4,12-dien-6-yn-5-yl-steroid-oxazolone (**7**). The ¹HNMR showed several signals for **7** at 0.88,

1.46, 2.30, 4.30-4.50 and 6.70 ppm for 1,4-diaza-cyclododeca-4,12-dien-6-yne ring; at 0.90 ppm for methyl group bound to steroid nucleus; at 1.58 ppm for methyl bound to oxazole ring; at 1.22-1.36, 1.55, 1.80-2.10, 2.46-3.10, 6.60 and 6.80 ppm for steroid moiety; at 6.88 ppm for oxazole ring. The ¹³CNMR display some signals at 13.80 ppm for methyl bound to steroid nucleus; at 19.91 ppm for methyl bound to oxazole ring; at 19.42, 23.03, 28.60, 34.44 and 48.42-50.00 ppm for 1,4-diaza-cyclododeca-4,12-dien-6-yne ring; at 21.70, 25.70-27.64, 28.92-31.34, 35.32-48.10, 50.24 and 108.65-145.46 ppm for steroid moiety; at 91.53 ppm for oxazole ring; at 149.72-159.86 ppm for imino group; at 220.30 ppm for ketone group. Finally, the mass spectrum from **7** showed a molecular ion (m/z) 471.28.

3.2 Physicochemical parameters of 2-7.

There are studies which suggest some physicochemical parameters such as molar volume (M_V) and molar refractivity (M_R) are chemical tools that correlate with different biological properties which may depend on the characteristics of each substituent involved in the chemical structure of a molecule. In this investigation, both M_V and M_R descriptors were determined using a previous method reported [30]. The theoretical results showed (Table 1) that M_V and M_R were higher for **7** compared with **2-6**. This phenomenon suggests that steric hindrance, conformational preferences, and internal rotation may be two factors which influence the biological activity to exert by **7** on some biological model. However, another type of physicochemical factors such as hydrogen bond donor groups (HBD) and hydrogen bond acceptor groups (HBA), topological polar surface area (TPSA) has been used to predict the biological activity of some compounds in several theoretical models [31]. These physicochemical parameters (Table 1) were determined using the Spartan 6.0 software; the theoretical data showed that the HBA value was <10 and the HBD value was <5 for compounds **2-7**, this phenomenon suggests that these compounds may be well absorbed such happening with another type of compounds²⁹). Other results showed that polar surface area (PSA) for **2-6** was < 100 Å values; it is noteworthy that some reports suggest that PSA < 140 Å values may condition the ability of some drugs to good oral absorption and exhibit some biological activity [32].

Table 1. Physicochemical parameters of compounds 2-7. The values were calculated using both ACD/Labs and Spartan softwares.

Parameters	2	3	4	5	6	7
Molar Refractivity (cm ³)	98.44	88.77	103.05	120.90	124.19	137.98
Molar Volume (cm ³)	279.40	269.80	307.50	359.50	375.80	371.50
Polarizability (cm ³)	39.02	35.19	40.85	47.93	49.23	54.70
Parachor (cm ³)	78.10	683.10	805.40	961.20	993.10	982.20
Index of refraction	1.62	1.57	1.58	1.58	1.57	1.66
Surface Tension (dyne/cm)	57.10	41.00	47.00	51.10	48.70	48.80
PSA Å ²	86.58	36.04	37.97	58.49	53.46	38.44
Density g/cm ³	1.28	1.15	1.26	1.21	1.19	1.26
HBD	2	1	0	1	0	0
HBA	6	3	4	5	5	4

3.3 Pharmacophore evaluation.

The pharmacophore model can furnish a new insight to design novel molecules that can enhance or inhibit the function of the target and will be useful in drug discovery strategies. Therefore, in this study, LigandScout software [33] was used to develop a pharmacophore model of compounds **2** and **3**. The results showed

in Figures 4 and 5 indicated that there is a different type of functional groups involved in the compounds **2** to **7** that can interact via hydrophobic contacts or as hydrogen bond acceptors or as hydrogen bond donor with some biomolecules.

3.4 Evaluation of interaction between compounds 2-7 with both COX1-1 and COX-2.

Since several years ago, some theoretical models have been used to predict the interaction of some drugs with protein or enzymes [32].




Figure 4. Scheme represents a pharmacophore from both compounds **2** (A), **3** (B) and **4**(C) using the LigandScout software. The model involves a methyl group (yellow) hydrogen bond acceptors (HBA, red) and hydrogen bond donor (HBD, green).




Figure 5. Theoretical pharmacophore from both compounds **5** (D), **6** (E) and **7** (F) using the LigandScout software. The model involves a methyl group (yellow) hydrogen bond acceptors (HBA, red) and hydrogen bond donor (HBD, green).




Figure 6. The scheme shows the binding sites of compound **7** with some amino acid residues involved on both COX 1 (2OyU [I]) and COX 2 (3LN1 [II]) enzymes. The visualization was carried out using DockingServer software.

Therefore, in this study was carried out a theoretical analysis on the interaction of compounds **7** with both COX1-1 (2OYU) and COX-2 (3LN1) using a Docking model [14] using both indomethacin and Rofecoxib as controls. The results showed the interaction of both indomethacin and compound **7** were only in two types of amino acid residues involved in the surface of the

2OYU protein, such as Tyr₅₅, Pro₆₇ (Figure 6 and Tables 2 and 3). Other theoretical data showed a similar interaction between both Rofecoxib and compound **7** with some Ser₂₃, Pro₂₅, Gln₂₇, Tyr₄₀, Asn₅₃ amino acid residues of COX-2 (3LN1). All these data suggest that there are differences between the interaction of compound **7** with both COX 1 and COX 2 compared with the bound of indomethacin and rofecoxib with this type of enzymes.

Table 2. Physicochemical parameters of compounds **2-7**. The values were calculated using both ACDLabs and Spartan softwares.

I-----Compounds-----I						
Parameters	2	3	4	5	6	7
Molar Refractivity (cm ³)	98.4	88.7	103.0	120.9	124.1	137.9
Molar Volume (cm ³)	279.4	269.8	307.5	359.5	375.8	371.5
Polarizability (cm ³)	39.0	35.1	40.8	47.9	49.2	54.7
Parachor (cm ³)	78.1	683.1	805.4	961.2	993.1	982.0
Index of refraction	1.6	1.5	1.5	1.5	1.5	1.6
Surface Tension (dyne/cm)	57.1	41.0	47.0	51.1	48.7	48.8
PSA Å ²	86.58	36.04	37.97	58.49	53.46	38.4
Density g/cm ³	1.2	1.1	1.2	1.2	1.1	1.2
HBD	2	1	0	1	0	0
HBA	6	3	4	5	5	4

Table 3. Residue Aminoacids involved in the interaction between both steroid-oxazolone derivative (compound **7**) and Rofecoxib with COX-2 enzyme (3LN1).

Compound	Aminoacid residues
steroid-oxazolone derivative	Ser ₂₃
	Pro ₂₅
	Gln ₂₇
	Tyr ₄₀
	Asn ₅₃
	Thr ₅₅
Rofecoxib	Val ₁₅₁
	Ser ₂₃
	Pro ₂₅
	Gln ₂₇
	Tyr ₄₀
	Asn ₅₃
	Lys ₁₅₂

3.5 Thermodynamic parameters.

Analyzing the above mentioned data and other types of reports which suggest that the drug-protein interaction could involve other types of intramolecular interactions [33], in study a theoretical ass was carried out to evaluate some thermodynamic factors involved in the interaction of the compound **7** with both 2OYU and 3LN1 proteins such as 1) free energy of binding which determinate the energy value that require a molecule to interact with a protein in a water environment. 2) Electrostatic energy that is the product of electrical charge and electrostatic potential, which are involved in the ligand-protein system; 3) total intermolecular energy and 4) Van der Waals (vdW) + hydrogen bond (Hbond) + desolvation energy (Desolv. Energy; which have an influence on the movement of water molecules into or out of the ligand-protein system) using a theoretical model [14]. The results (Tables 4 and 5) showed that there are differences in the thermodynamic parameters of compound **7** compared to both indomethacin (COX

1-inhibitor) [34] and rofecoxib (COX-2 antagonist) [35]. This phenomenon suggests that these differences could be translated as a higher inhibition of the biological activity of COX 1 (2OYU) in

the presence of compound 7 in comparison with indomethacin. In addition, a lower inhibition of COX 2 (3LN1) with the compound 7 compared with rofecoxib.

Table 4. Thermodynamic parameters involve in the interaction of both steroid-oxazolone derivative and Indometacin with COX-1 enzyme (2oyu).

Compound	Est. Free Energy of Binding (kcal/mol)	Inhibition Constant, Ki (μM)	vdW + Hbond + desolv Energy (kcal/mol)	Electrostatic Energy (kcal/mol)	Total Intermol. Energy (kcal/mol)	Interact Surface
Steroid-oxazolone derivative (4)	-6.47	18.01	-6.81	0.04	-6.77	628.614
Indometacin	-5.32	126.53	-6.24	-0.19	-6.43	576.698

Table 5. Thermodynamic parameters involve in the interaction of both steroid-oxazolone derivative and Rofecoxib with COX-2 enzyme (3LN1).

Compound	Est. Free Energy of Binding (kcal/mol)	Inhibition Constant, Ki (μM)	vdW + Hbond + desolv Energy (kcal/mol)	Electrostatic Energy (kcal/mol)	Total Intermol. Energy (kcal/mol)	Interact Surface
Steroid-oxazolone derivative (4)	-6.15	30.81	-6.36	0.09	-6.45	673.193
Rofecoxib	-3.78	1.69	-4.90	0.18	-4.73	557.621

4. CONCLUSIONS

In this study was reported a facile synthesis of a steroid-oxazolone derivative using some chemical strategies. In addition, theoretical data suggest that the steroid-oxazolone derivative could

be a good candidate as COX-inhibitor translated as a possible drug for treatment of pain.

5. REFERENCES

- Okur, N.; Apaydin, S.; Yavaşoğlu, N.; Yavaşoğlu, A.; Karasulu, H. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. *International journal of pharmaceutics* **2011**, *416*, 136-144, <https://doi.org/10.1016/j.ijpharm.2011.06.026>.
- Kearney, P.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *British Medical Journal* **2006**, *332*, 1302-1308, <https://doi.org/10.1136/bmj.332.7553.1302>.
- Amadio Jr, P.; Cummings, D.; Amadio, P. Nonsteroidal anti-inflammatory drugs: tailoring therapy to achieve results and avoid toxicity. *Postgraduate Medicine* **1993**, *93*, 73-97, <https://doi.org/10.1080/00325481.1993.11701639>
- Zikowski, D.; Hord, A.; Haddox, D.; Glascock, J. Ketorolac-induced bronchospasm. *Anesthesia and Analgesia* **1993**, *76*, 417-419.
- Curry, S.; Cogar, S.; Cook, J. Nonsteroidal anti-inflammatory drugs: a review. *Journal of the American Animal Hospital Association* **2005**, *41*, 298-309, <https://doi.org/10.5326/0410298>.
- Suleyman, H.; Demircan, B.; Karagoz, Y. Anti-inflammatory and side effects of cyclo-oxygenase inhibitors. *Pharmacological Reports* **2007**, *59*, 247-258.
- Ahmadi, A.; Khalili, M.; Hajikhani, R.; Naserbakht, M. New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats. *Pharmacology Biochemistry and Behavior* **2011**, *98*, 227-233, <https://doi.org/10.1016/j.pbb.2010.12.019>.
- Yogeeswari, P.; Menon, N.; Semwal, A.; Arjun, M.; Sriram, D. Discovery of molecules for the treatment of neuropathic pain: Synthesis, antiallodynic and antihyperalgesic activities of 5-(4-nitrophenyl) furoic-2-acid hydrazones. *European journal of*

- Medicinal Chemistry* **2011**, *46*, 2964-2970, <https://doi.org/10.1016/j.ejmech.2011.04.021>.
- Amir, M.; Kumar, H.; Khan, S.; Synthesis and pharmacological evaluation of pyrazoline derivatives as new anti-inflammatory and analgesic agents. *Bioorganic and Medicinal Chemistry letters* **2008**, *18*, 918-922, <https://doi.org/10.1016/j.bmcl.2007.12.043>.
- Teodori, E.; Baldi, E.; Dei, S.; Gualtieri, F.; Romanelli, M.; Scapocchi, S.; Matucci, R. Design, Synthesis, and Preliminary Pharmacological Evaluation of 4-Aminopiperidine Derivatives as N-Type Calcium Channel Blockers Active on Pain and Neuropathic Pain. *Journal of Medicinal Chemistry* **2004**, *47*, 6070-6081, <https://doi.org/10.1021/jm049923l>.
- Cleves A.; Jain A. Knowledge-guided docking: accurate prospective prediction of bound configurations of novel ligands using Surflex-Dock. *Journal of Computer-Aided Molecular Design* **2015**, *29*, 485-489, <https://doi.org/10.1007/s10822-015-9846-3>.
- Figuerola, L.; Diaz, F.; Rosas, M.; Mateu, V.; Montano, E.; Hau, L.; Alfonso, J. Design and synthesis of two steroid derivatives from 2-nitroestrone and theoretical evaluation of their interaction with BRCA-1. *Asian Journal of Green Chemistry* **2019**, *3*, 2016-235, <https://dx.doi.org/10.22034/ajgc.2018.144189.1093>.
- Obot, I.; Obi-Egbedi, N. Theoretical study of benzimidazole and its derivatives and their potential activity as corrosion inhibitors. *Corrosion Science* **2010**, *52*, 657-660, <https://doi.org/10.1016/j.corsci.2009.10.017>.
- Pajouhesh, H.; Lenz, G. Medicinal chemical properties of successful central nervous system drugs. *NeuroRx* **2005**, *2*, 541-553, <https://doi.org/10.1602/neurorx.2.4.541>.
- Lin, Y.; Cheng, C.; Shih, C.; Hwang, J.; Yu, C.; Lu, C. MIB: Metal Ion-Binding Site Prediction and Docking Server. *Journal of chemical information and modeling* **2016**, *56*, 2287-2291, <https://doi.org/10.1021/acs.jcim.6b00407>.

16. Istrate, F.; Buzas, A.; Jurberg, D.; Odabachian, Y.; Gagosz, F. Synthesis of functionalized oxazolones by a sequence of Cu (II)- and Au (I)-catalyzed transformations. *Organic Letters* **2008**, *10*, 925-928, <https://doi.org/10.1021/ol703077g>.
17. Cleaver, C.; Pratt, B. Polyamides from 2,2'-Bis-[5(4H)-oxazolones]. *Journal of the American Chemical Society* **1995**, *77*, 1541-1543, <https://doi.org/10.1021/ja01611a041>.
18. Yamashita, M.; Sang, H.; Koch, G.; Zimmermann, J.; Clapham, B.; Janda, K. Solid-phase synthesis of oxazolones and other heterocycles via Wang resin-bound diazocarbonyls. *Tetrahedron Letters* **2005**, *46*, 5495-5498, <https://doi.org/10.1016/j.tetlet.2005.06.061>.
19. Mazurkiewicz, R.; Pierwocha, A. 4-Phosphoranylidene-5(4H)-oxazolones-A novel synthesis and properties. *Monatshefte für Chemie* **1996**, *127*, 219-225, <https://doi.org/10.1007/BF00807402>.
20. H. Huang, G. He, G. Zhu, X. Zhu, S. Qiu, H. Zhu, Palladium-Catalyzed Intramolecular Cyclization of Ynamides: Synthesis of 4-Halo-oxazolones. *Journal Organic Chemistry* **2015**, *80*, 3480-3487, <https://doi.org/10.1021/acs.joc.5b00071>.
21. Beck, J. Nucleophilic displacement of aromatic nitro groups. *Tetrahedron* **1978**, *34*, 2057-2068, [https://doi.org/10.1016/0040-4020\(78\)89004-8](https://doi.org/10.1016/0040-4020(78)89004-8)
22. Takekoshi, T.; Wirth, J.; Heath, D.; Kochanowski, J.; Webber, M. Polymer syntheses via aromatic nitro displacement reaction. *Journal of Polymer Science: Polymer Chemistry Edition* **1980**, *18*, 3069-3080, <https://doi.org/10.1002/pol.1980.170181016>.
23. López-Ramos, M.; Figueroa-Valverde, L.; Herrera-Meza, S.; Rosas-Nexticapa, M.; Díaz-Cedillo, F.; García-Cervera, E.; Cahuich-Carrillo, R. Design and synthesis of a new steroid-macrocyclic derivative with biological activity. *Journal of Chemical Biology* **2017**, *10*, 69-84, <https://dx.doi.org/10.1007/s12154-017-0165-0>.
24. Hiegel, G.; Hogenauer, T.; Lewis, J. Preparation of N-chloroamides using trichloroisocyanuric acid. *Synthetic Communications* **2005**, *35*, 2091-2098, <https://doi.org/10.1081/SCC-200066703>.
25. Katritzky, A.; Majumder, S.; Jain, R. Microwave assisted N-chlorination of secondary amides. *Arkivoc* **2003**, *12*, 74-79, <http://dx.doi.org/10.3998/ark.5550190.0004.c09>.
26. Xiao, Y.; Wen, W.; Qian, L.; Bi, J. Synthesis of α -chloroamides in water. *Journal of American Chemical Society* **2018**, *140*, 506-514.
27. Hashmi, A.; Schuster, A.; Schmuck, M.; Rominger, F. Gold-Catalyzed Cyclization of Nonterminal Propargylic Amides to Substituted Alkylideneoxazolines and-oxazines. *European Journal of Organic Chemistry* **2011**, *24*, 4595-4602, <https://doi.org/10.1002/ejoc.201100342>.
28. Zhan, Z.; Yu, J.; Liu, H.; Cui, Y.; Yang, R.; Yang, W.; Li, J. A general and efficient FeCl₃-catalyzed nucleophilic substitution of propargylic alcohols. *The Journal of Organic Chemistry* **2006**, *71*, 8298-8301, <https://doi.org/10.1021/jo061234p>.
29. Figueroa, L.; Díaz, F.; García, E.; Pool, E.; Rosas, M.; López, M.; Vera, E. Design and synthesis of two triazonine-carbaldehyde derivatives using several chemical tools. *Journal of Saudi Chemical Society* **2018**, *22*, 183-197, <https://doi.org/10.1016/j.jscs.2016.03.003>.
30. Figueroa, L.; Diaz, F.; Lopez, M.; Garcia, E. Synthesis of pregnenolone-danazol-ethylenediamine conjugate: relationship between descriptors logP, π , Rm and Vm and its antibacterial activity in S. aureus V. cholera. *Medicinal Chemistry Research* **2011**, *20*, 847-853, <https://doi.org/10.1007/s00044-010-9408-0>.
31. Bandgar, B.; Gawande, S.; Bodade, R.; Gawande, N.; Khobragade, C. Synthesis and biological evaluation of a novel series of pyrazolechalcones as anti-inflammatory, antioxidant and antimicrobial agents. *Bioorganic and Medicinal Chemistry* **2009**, *17*, 8168-8173, <https://doi.org/10.1016/j.bmc.2009.10.035>.
32. Kitchen, D.; Decornez, H.; Furr, J.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. *Nature Reviews Drug Discovery* **2004**, *3*, 935-949, <https://doi.org/10.1038/nrd1549>.
33. Schneidman, D.; Nussinov, R.; Wolfson, H. Predicting molecular interactions in silico: II. Protein-protein and protein-drug docking. *Current Medicinal Chemistry* **2004**, *11*, 91-107, <https://doi.org/10.2174/0929867043456223>.
34. Mottarella, S.; Beglov, D.; Beglova, N.; Nugent, M.; Kozakov, D.; Vajda, S. Docking server for the identification of heparin binding sites on proteins. *Journal of Chemical Information and Modeling* **2014**, *54*, 2068-2078, <https://doi.org/10.1021/ci500115j>
35. Yamamoto, T.; Nozaki-Taguchi, N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. *Brain Research* **1996**, *739*, 104-110, [https://doi.org/10.1016/S0006-8993\(96\)00817-7](https://doi.org/10.1016/S0006-8993(96)00817-7).
36. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.; Charleson, S.; Cromlish, W.; Gordon, R. The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4'-methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2 inhibitor. *Bioorganic and Medicinal Chemistry Letters* **1999**, *9*, 1773-1778, [https://doi.org/10.1016/S0960-894X\(99\)00288-7](https://doi.org/10.1016/S0960-894X(99)00288-7).

6. ACKNOWLEDGEMENTS

The authors extend their sincere thanks to Dr. Cindy Rossina Saravia, Rector of the University Autonomous of Campeche for their support in carrying out this study.



© 2019 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).